MacroGenics | MGNX - Equity Capital And Reserves


MacroGenics reported $21.2M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Daiichi Sankyo JPY 1.7T 38.53B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Genmab DKK 5.96B 275M Jun/2026
Geron USD 218.61M 10.49M Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Merck USD 41.93B 3.94B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Xencor USD 503.23M 12.4M Jun/2026